Related Experiment Video
Updated: Sep 16, 2025
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy
Gloria Montebello1, Giuseppe Di Giovanni2,3,4
1Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, 2080 Msida, Malta.
Insights
Pediatric drug-resistant epilepsy (DRE) impacts millions. Targeting the endocannabinoid system (ECS) with compounds like cannabidiol (CBD) shows promise for seizure control and managing associated conditions.
Area of Science:
- Neuroscience
- Pharmacology
- Pediatrics
Background:
- Epilepsy affects over 12 million children globally, with 30% experiencing drug-resistant epilepsy (DRE).
- DRE is frequently associated with neuropsychiatric comorbidities, significantly diminishing quality of life.
- The endocannabinoid system (ECS) is crucial for neuromodulation, regulating neuronal excitability and synaptic plasticity throughout life.
Purpose of the Study:
- To explore the role of the endocannabinoid system (ECS) in pediatric epilepsies.
- To review the therapeutic potential of targeting the ECS for drug-resistant epilepsy (DRE).
- To discuss the efficacy and safety of cannabidiol (CBD) and other ECS-based strategies in pediatric epilepsy.
Main Methods:
- Review of preclinical and clinical studies on ECS components in pediatric epilepsy.
- Analysis of the therapeutic effects of cannabidiol (CBD) for specific epilepsy syndromes.
- Evaluation of emerging ECS-based strategies, including allosteric modulators and enzyme inhibitors.
Main Results:
- Alterations in ECS components are observed in pediatric epilepsies, indicating specific vulnerabilities.
- Cannabidiol (CBD) demonstrates significant efficacy in treating DRE and is approved for Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex.
- Other ECS-targeting strategies, like CB1 receptor modulators and FAAH/MAGL inhibitors, show potential for seizure reduction.
Conclusions:
- Targeting the ECS offers promising therapeutic avenues for pediatric DRE and associated comorbidities.
- Precision medicine approaches, tailoring ECS interventions to specific epilepsy syndromes, may enhance treatment outcomes.
- Long-term use of ECS-based therapies in children requires careful consideration due to the ECS's vital role in brain development.
Abstract:
Epilepsy affects over 12 million children worldwide, with approximately 30% classified as having drug-resistant epilepsy (DRE), often accompanied by neuropsychiatric comorbidities that severely impact quality of life. The endocannabinoid system (ECS) functions as a multifaceted neuromodulatory network regulating neuronal excitability, synaptic plasticity, and immune homeostasis from early life through adolescence and into aging. In pediatric epilepsies, alterations in ECS components, particularly CB1 receptor expression and endocannabinoid levels, reveal disorder-specific vulnerabilities and therapeutic opportunities. Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has shown strong preclinical and clinical efficacy in treating DRE and is approved for Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. Other ECS-based strategies, such as the use of CB1 receptor-positive allosteric modulators, can selectively enhance endogenous cannabinoid signaling where and when it is active, potentially reducing seizures in conditions like Dravet and absence epilepsy. Similarly, FAAH and MAGL inhibitors may help restore ECS tone without directly activating CB1 receptors. Precision targeting of ECS components based on regional expression and syndrome-specific pathophysiology may optimize seizure control and associated comorbidities. Nonetheless, long-term pediatric use must be approached with caution, given the critical role of the ECS in brain development.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...